To prove this, we measured β-galactosidase (β-Gal) in CML CD34+-treated with 100 nM Meds433 for 3 days, and a significant increase in β-Gal percentage was recorded (Fig. 5F). This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.